Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial.

OBJECTIVE To compare early and late side effects in prostate cancer patients with Stage T1b-T3 disease randomized to receive 70 Gy or 78 Gy. METHODS There were 189 patients randomized with a minimum follow-up of 2 years, that were available for this analysis. All patients were initially treated with a 4-field box to an isocenter dose of 46 Gy at 2 Gy per fraction. In the 70-Gy arm, treatment was continued to a reduced volume using a 4-field box technique. In the 78-Gy arm, treatment was continued to a reduced volume using a conformal 6-field arrangement. Side effects were graded on a 1-4 scale, adapted from Radiation Therapy Oncology Group and Late Effects Normal Tissue Task Force criteria. RESULTS No significant differences in acute rectal or bladder toxicity were seen between the two treatment techniques (p > 0.6 for all comparisons). The 5-year Kaplan-Meier risks of Grade 2 or higher late bladder toxicity were 20% and 9% for 70-Gy and 78-Gy groups, respectively (log rank, p = 0.8). The 5-year risks of Grade 2 or higher late rectal toxicity were 14% and 21% for 70 Gy and 78 Gy, respectively (p = 0.4). Dose-volume histogram analysis of the 78-Gy patients showed a significant correlation between the percentage of rectum irradiated to 70 Gy or greater and the likelihood of developing late rectal complications. Patients with more than 25% of the rectum receiving 70 Gy or greater had a 5-year risk of Grade 2 or higher complications of 37% compared to 13% for patients with 25% or less (p = 0.05). All three Grade 3 complications occurred when greater than 30% of the rectum received 70 Gy or more. CONCLUSION The overall rate of complications was similar in both treatment arms. However, there is evidence for a significant increase in late rectal complications when more than 25% of the rectum received 70 Gy or greater. This parameter may serve as a benchmark for the design of future three-dimensional conformal trials.

[1]  J. Diamond,et al.  A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. , 1987, International journal of radiation oncology, biology, physics.

[2]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[3]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[4]  M. Zelefsky,et al.  Long term tolerance of high dose three‐dimensional conformal radiotherapy in patients with localized prostate carcinoma , 1999, Cancer.

[5]  L. Verhey,et al.  Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.

[6]  T E Schultheiss,et al.  Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.

[7]  A. Hanlon,et al.  Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. , 1997, International journal of radiation oncology, biology, physics.

[8]  M Goitein,et al.  Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. , 1993, International journal of radiation oncology, biology, physics.

[9]  M M Urie,et al.  Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. , 1996, International journal of radiation oncology, biology, physics.

[10]  E. K. Harris,et al.  Survivorship Analysis for Clinical Studies , 1990 .

[11]  G J Kutcher,et al.  Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy--a dose-escalation study. , 1998, Radiology.

[12]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[13]  H. Bartelink,et al.  LATE EFFECTS TOXICITY SCORING : THE SOMA SCALE , 1995 .

[14]  G E Hanks,et al.  Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. , 1992, International journal of radiation oncology, biology, physics.

[15]  G Starkschall,et al.  Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. , 1996, International journal of radiation oncology, biology, physics.

[16]  T E Schultheiss,et al.  Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. , 1996, International journal of radiation oncology, biology, physics.

[17]  A. V. von Eschenbach,et al.  External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. , 2000, International journal of radiation oncology, biology, physics.

[18]  W. Sause,et al.  Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate--analysis of RTOG study 75-06. , 1987, International journal of radiation oncology, biology, physics.

[19]  D. Dearnaley,et al.  Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial , 1999, The Lancet.

[20]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[21]  E. Crawford,et al.  Advanced prostate cancer , 1999, Prostate Cancer and Prostatic Diseases.